Cancer Research and Treatment

Original Article

Loss of LKB1 Protein Expression Correlates with Increased Risk of Recurrence and Death in Patients with Resected, Stage II or III Colon Cancer: Maria Sfakianaki, Chara Papadaki, Maria Tzardi, Maria Trypaki, Sardar Alam, Eleni D. Lagoudaki, Ippokratis Messaritakis, Odysseas Zoras, Dimitris Mavroudis, Vassilis Georgoulias, John Souglakos; Cancer Res Treat. 2019;51(4):1518-1526. Published online March 20, 2019; DOI: https://doi.org/10.4143/crt.2019.008

Abstract PDF Supplementary Material PubReader ePub

Purpose
The purpose of this study was to investigate the prognostic significance of liver kinase b1 (LKB1) loss in patients with operable colon cancer (CC).
Materials and Methods
Two hundred sixty-two specimens from consecutive patients with stage III or high-risk stage II CC, who underwent surgical resection with curative intent and received adjuvant chemotherapy with fluoropyrimidine and oxaliplatin, were analyzed for LKB1 protein expression loss, by immunohistochemistry as well as for KRAS exon 2 and BRAFV600E mutations by Sanger sequencing and TS, ERCC1, MYC, and NEDD9 mRNA expression by real-time quantitative reverse transcription polymerase chain reaction.
Results
LKB1 expression loss was observed in 117 patients (44.7%) patients and correlated with right-sided located primaries (p=0.032), and pericolic lymph nodes involvement (p=0.003), BRAFV600E mutations (p=0.024), and TS mRNA expression (p=0.041). Patients with LKB1 expression loss experienced significantly lower disease-free survival (DFS) (hazard ratio [HR], 1.287; 95% confidence interval [CI], 1.093 to 1.654; p=0.021) and overall survival (OS) (HR, 1.541; 95% CI, 1.197 to 1.932; p=0.002), compared to patients with LKB1 expressing expressing tumors. Multivariate analysis revealed LKB1 expression loss as independent prognostic factor for both decreased DFS (HR, 1.217; 95% CI, 1.074 to 1.812; p=0.034) and decreased OS (HR, 1.467; 95% CI, 1.226 to 2.122; p=0.019).
Conclusion
Loss of tumoral LKB1 protein expression, constitutes an adverse prognostic factor in patients with operable CC.

Citations

Citations to this article as recorded by

Cafestol inhibits colon cancer cell proliferation and tumor growth in xenograft mice by activating LKB1/AMPK/ULK1-dependent autophagy
Yuemei Feng, JiZhuo Yang, Yihan Wang, Xue Wang, Qian Ma, Yalin Li, Xuehui Zhang, Songmei Wang, Qiao Zhang, Fei Mi, Yanjiao Wang, Dubo Zhong, Jianzhong Yin
The Journal of Nutritional Biochemistry.2024; 129: 109623. CrossRef
The Prognostic Significance of NEDD9 Expression in Human Cancers: A Systematic Review, Meta-Analysis, and Omics Exploration
Jehad A. Yasin, Ramez M. Odat, Fares A. Qtaishat, Mohammad-Amer A. Tamimi, Muaath I. Alsufi, Osama M. Younis, Leen A. Alkuttob, Anwaar Saeed
Technology in Cancer Research & Treatment.2024;[Epub] CrossRef
Phe354Leu polymorphism of the liver kinase B1 gene as a prognostic factor in adult egyptian patients with acute myeloid leukemia
Ola A. Hussein, Hany A. Labib, Rasha Haggag, Maha Mahmoud Hamed Sakr
Heliyon.2023; 9(5): e15415. CrossRef
Unraveling the Role of Molecular Profiling in Predicting Treatment Response in Stage III Colorectal Cancer Patients: Insights from the IDEA International Study
Ippokratis Messaritakis, Eleni Psaroudaki, Konstantinos Vogiatzoglou, Maria Sfakianaki, Pantelis Topalis, Ioannis Iliopoulos, Dimitrios Mavroudis, John Tsiaoussis, Nikolaos Gouvas, Maria Tzardi, John Souglakos
Cancers.2023; 15(19): 4819. CrossRef
Prognostic Value of KRAS Mutations in Colorectal Cancer Patients
Asimina Koulouridi, Michaela Karagianni, Ippokratis Messaritakis, Maria Sfakianaki, Alexandra Voutsina, Maria Trypaki, Maria Bachlitzanaki, Evangelos Koustas, Michalis V. Karamouzis, Anastasios Ntavatzikos, Anna Koumarianou, Nikolaos Androulakis, Dimitrio
Cancers.2022; 14(14): 3320. CrossRef
Investigation of Microbial Translocation, TLR and VDR Gene Polymorphisms, and Recurrence Risk in Stage III Colorectal Cancer Patients
Ippokratis Messaritakis, Asimina Koulouridi, Eleni Boukla, Maria Sfakianaki, Konstantinos Vogiatzoglou, Michaela Karagianni, Nikolaos Gouvas, John Tsiaoussis, Evangelos Xynos, Elias Athanasakis, Dimitrios Mavroudis, Maria Tzardi, John Souglakos
Cancers.2022; 14(18): 4407. CrossRef
Peutz-Jeghers syndrome: what has been known for 125 years of research? (review)
Tatiana A. Savelyeva, D. Yu. Pikunov, A. M. Kuzminov, A. S. Tsukanov
Koloproktologia.2021; 20(2): 85. CrossRef
PKM2 Expression as Biomarker for Resistance to Oxaliplatin-Based Chemotherapy in Colorectal Cancer
Maria Sfakianaki, Chara Papadaki, Maria Tzardi, Maria Trypaki, Stavroula Manolakou, Ippokratis Messaritakis, Zenia Saridaki, Elias Athanasakis, Dimitrios Mavroudis, John Tsiaoussis, Nikolaos Gouvas, John Souglakos
Cancers.2020; 12(8): 2058. CrossRef
LKB1 inactivation leads to centromere defects and genome instability via p53-dependent upregulation of survivin
Li-Yan Jin, Kui Zhao, Long-Jiang Xu, Rui-Xun Zhao, Kaitlin D. Werle, Yong Wang, Xiao-Long Liu, Qiu Chen, Zhuo-Jun Wu, Ke Zhang, Ying Zhao, Guo-Qin Jiang, Feng-Mei Cui, Zhi-Xiang Xu
Aging.2020; 12(14): 14341. CrossRef
Genetic Variants in DNA Repair Pathways as Potential Biomarkers in Predicting Treatment Outcome of Intraperitoneal Chemotherapy in Patients With Colorectal Peritoneal Metastasis: A Systematic Review
Emma C. Hulshof, Lifani Lim, Ignace H. J. T. de Hingh, Hans Gelderblom, Henk-Jan Guchelaar, Maarten J. Deenen
Frontiers in Pharmacology.2020;[Epub] CrossRef

6,811 View
184 Download
9 Web of Science
10 Crossref

First
Prev
Page of 1
Next
Last

Search